home / stock / lumo / lumo news

LUMO News and Press, Lumos Pharma Inc. From 05/01/24

Stock Information
Company Name: Lumos Pharma Inc.
Stock Symbol: LUMO
Market: NASDAQ
Website: lumos-pharma.com
Menu
LUMO LUMO Quote LUMO Short LUMO News LUMO Articles LUMO Message Board
Get LUMO Alerts

News, Short Squeeze, Breakout and More Instantly...
LUMO - Expected US Company Earnings on Wednesday, May 1st, 2024

Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
LUMO - Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase ...

LUMO - InvestorNewsBreaks - Lumos Pharma Inc. (NASDAQ: LUMO) Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate

Lumos Pharma (NASDAQ: LUMO) , a biopharmaceutical company advancing an oral therapeutic candidate for pediatric growth hormone deficiency (“PGHD”) through phase 2 clinical trials, has received a notice of allowance for a submitted patent. The notice was received from the U.S. P...

LUMO - Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042

AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that on Thursday, March 14, 2024, the Company recei...
LUMO - Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript

2024-03-07 17:45:08 ET Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Conference March 07, 2024 04:30 PM ET Company Participants Lisa Miller - Vice President, IR Rick Hawkins - CEO and Chairman John McKew - President and CSO Duke Pitukcheewanont - CMO Lori La...

LUMO - Lumos Pharma GAAP EPS of -$4.18 misses by $0.13, revenue of $2.05M beats by $0.83M

2024-03-07 16:32:56 ET More on Lumos Pharma Lumos Pharma, Inc. 2023 Q3 - Results - Earnings Call Presentation Lumos Pharma promotes Pisit Pitukcheewanont to chief medical officer Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for...

LUMO - Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Moderate PGHD Met All Primary and Secondary Endpoints Pisit “Duke” ...
LUMO - Expected US Company Earnings on Thursday, March 7th, 2024

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...

LUMO - Notable earnings after Thursday's close

2024-03-06 17:35:33 ET Major earnings expected after the bell on Thursday include: Costco Wholesale Corporation ( COST ) Broadcom ( AVGO ) DocuSign ( DOCU ) Marvell Technology ( MRVL ) Petróleo Brasileiro ( PBR ) Read the full article o...

LUMO - Lumos Pharma FY 2023 Earnings Preview

2024-03-06 17:20:06 ET More on Lumos Pharma Lumos Pharma, Inc. 2023 Q3 - Results - Earnings Call Presentation Lumos Pharma promotes Pisit Pitukcheewanont to chief medical officer Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for...
Previous 10 Next 10